Several small-cap biotech and healthcare names posted notable gains in Thursday's after-hours trading session, with investors reacting to recent corporate updates and clinical milestones.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) rose 5.88% to $1.08 as of 7:56 PM EST. While there was no fresh news on Thursday, the company recently announced on December 15 that it had entered into a definitive agreement with YA II PN, Ltd. for a registered direct offering of its ordinary shares. Inspira also signed a Standby Equity Purchase Agreement (SEPA) with YA, providing additional equity financing flexibility.
Galectin Therapeutics Inc. (GALT) added 1.79% to close at $6.27 in after-hours trading at 7:54 PM EST. The stock moved higher despite no new corporate developments being reported during the day.
MediciNova, Inc. (MNOV) advanced 4.83% to $1.52 after announcing the successful completion of patient enrollment in its Phase 2 OXTOX study. The trial, led by Dr. Janette Vardy and Dr. Haryana Dhillon, is evaluating MN-166 (ibudilast) for the prevention of chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients. A total of 100 patients have been randomized across two treatment arms at 11 clinical sites in Australia, with recruitment now officially closed.
Marker Therapeutics, Inc. (MRKR) gained 5.56% to $1.33 in after-hours trading. The move came without any new company-specific announcements on Thursday.
Sharps Technology, Inc. (STSS) climbed nearly 4% to $2.09 as of 7:24 PM EST. Shares advanced despite no fresh updates from the company.
DiaMedica Therapeutics Inc. (DMAC) rose 2.89% to $8.55 after reporting a productive pre-IND meeting with the U.S. Food and Drug Administration regarding its planned study of DM199 in preeclampsia. The FDA requested one additional non-clinical study in a rabbit model, with results expected by the second quarter of 2026.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) edged higher by 1.36% to $8.21 in after-hours trading. While no new developments were reported Thursday, the company recently announced completion of its Phase 1a study of CRB-913 and initiation of the Phase 1b CANYON-1 trial, targeting chronic obesity management.
ProMIS Neurosciences, Inc. (PMN) added 0.83% to $8.49 in after-hours trading at 6:35 PM EST, recovering slightly after a 5.61% decline during the regular session. Earlier in the day, the company announced completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial, evaluating PMN310 for Alzheimer's disease.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.